IN-POLYVANTIS
For the first time, two powerhouse organizations, SABIC's Functional Forms and Röhm’s Acrylic Products, have joined forces to form POLYVANTIS.
The newly established entity offers comprehensive, multi-material and industry-leading product portfolio, unique technical knowledge, and application-based expertise in sheets and films across various sectors, including building and construction, electrical and electronics, automotive, air and rail, healthcare and security, and lighting and signage. Under the iconic PLEXIGLAS® / ACRYLITE® and LEXAN™ brands, POLYVANTIS delivers its solutions in polymethylmethacrylate (PMMA) and polycarbonate (PC).
The organization boasts a workforce of approximately 1,500 employees and operates 15 production sites across the Americas, Europe, Asia, and Africa.
As previously announced, a Board of Directors consisting of three functions will lead POLYVANTIS. Dr. Sandeep Dhawan as Chief Executive Officer, Peter Stubbe as Chief Financial Officer, and Dr. Wolfgang Pöffel as Chief Transformation and Integration Officer.
“The combination of coveted brands under one umbrella will enable growth for our customers. We will join forces to harness our innovative strength, build holistic solutions for our customers and create a stronger presence worldwide,” said Sandeep Dhawan, Chief Executive Officer of POLYVANTIS. “With many years of experience in technology and product development, POLYVANTIS will provide unique and unparalleled technical and application-based expertise.”
POLYVANTIS fosters a forward-thinking culture focused on continuous innovation and improvement. For decades, customers have relied on the comprehensive product portfolio, capabilities, innovative thinking, and tenacity of the people who make up POLYVANTIS. To learn more about POLYVANTIS and its unique approach, visit our website.
About POLYVANTIS
POLYVANTIS is a global, multi-material player with some of the most coveted and iconic brands in the industry – such as PLEXIGLAS® and ACRYLITE® for polymethylmethacrylate semi-finished products and LEXAN™ for polycarbonate sheets and films. With 1,500 employees and 15 production sites worldwide, POLYVANTIS offers unmatched global capabilities, providing customers with innovative solutions in sheets and films for the building and construction, electrical and electronics, automotive, air and rail, healthcare and security, and lighting and signage markets. To learn more about the latest at POLYVANTIS, follow us on LinkedIn or our website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240901257346/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intelecy announces Anna Olsson’s promotion to Chief Operating Officer13.9.2024 16:40:00 CEST | Press release
Intelecy, a leading Norwegian industrial AI company, is excited to announce the promotion of Anna Olsson from Chief Commercial Officer (CCO) to Chief Operating Officer (COO). This move comes as the company accelerates its global expansion, following a year of remarkable growth and successful project deliveries across multiple countries. Anna Olsson, who joined Intelecy with over 20 years of experience in the software industry, has been instrumental in driving the company’s commercial strategy and internationalization. With a robust background in industrial AI and experience from global roles, including her time at Cognite and Microsoft, Olsson’s leadership will now focus on optimizing operations to meet Intelecy’s growing global demand and supporting its continued innovation in AI-driven process optimization and energy management. "I've witnessed the industrial sector’s eagerness to embrace AI for optimizing production, streamlining processes, and driving sustainability. Yet, many stru
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa13.9.2024 11:00:00 CEST | Press release
Inhalation of colistimethate sodium via the I-neb® Adaptive Aerosol Delivery System (CMS I-neb) significantly reduced pulmonary exacerbations and improved quality of life in non-cystic fibrosis bronchiectasis (NCFB) patients colonized with P. aeruginosa Both trials showed that CMS I-neb was generally well tolerated, with no major safety concerns, and bronchospasm occurred in fewer than 5% of patients Zambon is continuing to work with regulatory authorities with the goal of making colistimethate sodium delivered via a customized inhalation device available to patients with bronchiectasis and P. aeruginosa chronic infection Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the online publication of its Phase 3 PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicinejournal. The PROMIS studies assessed the efficacy and safety of inhaled colistimethate sodium administere
Intelsat Signs Hybrid Media Deal Distributing Hearst Networks EMEA Content13.9.2024 09:00:00 CEST | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, successfully launched a hybrid television content distribution service to deliver Hearst Networks EMEA (formerly known as A+E Networks EMEA) channels to hundreds of points across Europe thanks to its seamless satellite-terrestrial connection. “Growing global media customers like Hearst Networks EMEA want to work with a single operator that can provide seamless connections from satellite to ground-based Internet Protocol distribution networks,” said Rhys Morgan, regional vice president, EMEA, Media and Networks. “Intelsat has visibility across the full distribution network, even when it spans multiple technologies and can enable customers to reach more end users.” In order to reach a wide group of viewers, content providers typically use multiple distribution mediums such as direct-to-home (DTH), cable and IPTV. Hearst Networks EMEA needed to maximize the reach of its flagship channels, The H
NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services13.9.2024 08:30:00 CEST | Press release
Under a multi-year contract, the Luxembourg-based satellite operator SES will deliver secure and resilient high-performance connectivity for NATO member governments The NATO Support and Procurement Agency (NSPA) has awarded SES a contract to deliver secure high-performance low-latency satellite services via its medium earth orbit (MEO) constellation, enabling global missions for NATO member government organisations, agencies and military. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910404747/en/ NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services (Photo: Business Wire) The MEO Global Services (MGS) award represents a three-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at USD 200M, with two one-year options. This is the first award under the Global Commercially Contracted Satellite Communications Support Partnership (GCC SATCOM SP) established by the U.
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types13.9.2024 08:00:00 CEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). “Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom